Laxminarayan Bhat
Featured in: 
psychiatrictimes.com
Articles
-
3 weeks ago |
psychiatrictimes.com | Heidi Anne Duerr |Laxminarayan Bhat
Reviva Pharmaceuticals announced positive results from their phase 3 RECOVER open label extension of brilaroxazine (RP5063) for patients with schizophrenia.1,2 The trial looked at long-term safety, tolerability, and efficacy of once daily brilaroxazine over a 1-year period.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →